Aspirin protects against preeclampsia via p38MAPK signaling pathway

Purpose: To investigate the protective effect of aspirin against preeclampsia and the involvement of p38MAPK signaling pathway in the process.Methods: Sixty pregnant women who underwent antenatal care and delivery at Chancheng Central Hospital from September 2020 to September 2022 were selected and equally assigned to control group (CG) and experimental group (EG). From the 12th week of gestation, EG was administered 100 mg of aspirin and 1000 mg of calcium carbonate daily, while CG was given only 1000 mg of calcium carbonate daily. Both groups were treated up to the 35th week of gestation. Thereafter, blood samples were taken for measurement of serum levels of p38MAPK. In addition, the blood pressure of the women was measured. The incidence of preeclampsia and maternal-infant outcomes were assessed.Results: EG had a lower p38MAPK level at week 35 of pregnancy, and lower blood pressure levels at the 27th and 35th weeks of gestation, than CG (p < 0.05). There were 5 cases of preeclampsia (16.7 %) in EG, and 13 cases (43.3 %) of preeclampsia in CG, with a lower incidence of preeclampsia in EG than in CG (ꭓ2 = 5.079, p < 0.05). The numbers of newborns through premature delivery and cesarean section, as well as Apgar score ≤ 7 were lower in EG than in CG (p < 0.05).Conclusion: Aspirin exerts a protective effect against preeclampsia through via p38MAPK signaling pathway. Therefore, aspirin treatment may be useful in reducing the incidence of preeclampsia and improving maternal-infant outcomes. However, further clinical trials are recommended prior to application in clinical practice

High-Capacity, Dendrite-Free, and Ultrahigh-Rate Lithium-Metal Anodes Based on Monodisperse N-Doped Hollow Carbon Nanospheres

To unlock the great potential of lithium metal anodes for high-performance batteries, a number of critical challenges must be addressed. The uncontrolled dendrite growth and volume changes during cycling (especially, at high rates) will lead to short lifespan, low Coulombic efficiency (CE), and security risks of the batteries. Here it is reported that Li metal anodes, employing the monodisperse, lithiophilic, robust, and large-cavity N-doped hollow carbon nanospheres (NHCNSs) as the host, show remarkable performances—high areal capacity (10 mAh cm−2), high CE (up to 99.25% over 500 cycles), complete suppression of dendrite growth, dense packing of Li anode, and an extremely smooth electrode surface during repeated Li plating/stripping. In symmetric cells, a highly stable voltage hysteresis over a long cycling life >1200 h is achieved, and a low and stable voltage hysteresis can be realized even at an ultrahigh current density of 64 mA cm−2. Furthermore, the NHCNSs-based anodes, when paired with a LiFePO4 (LFP) cathode in full cells, give rise to highly improved rate capability (104 mAh g−1 at 10 C) and cycling stability (91.4% capacity retention for 200 cycles), enabling a promising candidate for the next-generation high energy/power density batteries

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Abstract Objective To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. Methods This was an open-label, single-arm and multicenter clinical trial. The ORR was the interim primary objective, and the DCR, AEs and QOL were the secondary objectives. The impact of factors on efficacy outcomes, the change trend of CA125 and the artificial platinum-free interval were exploratory endpoints. Results Totally, 115 patients were enrolled in this study and included in the ITT population. Moreover, 101 patients were included in the safety population. The median follow-up time was 4 months (IQR 2–6). In the ITT population, the confirmed ORR was 37.4% (95% CI, 28.4–46.4%), and the DCR was 65.2% (95% CI, 56.4–74.1%). The previous response status to platinum-based chemotherapy and baseline CA125 levels were significantly correlated with the ORR. The ORR was significantly higher in patients with a CA125 decrease after the first cycle than in the patients with a CA125 increase. The most common grade 3 or higher AE was hand-foot syndrome (3 [3.0%] of 101 patients). No statistically significant differences existed between the baseline and the postbaseline questionnaires. Conclusions For patients who experience platinum-resistant and platinum-refractory relapse, the use of PLD may be acceptable because of the associated satisfactory efficacy, low frequency of AEs and high patient QOL. Moreover, a low CA125 level at baseline and a reduction in CA125 after the first cycle are predictive factors for satisfactory efficacy